The anti-CD38 monoclonal antibody isatuximab (Isa) exerts anti-myeloma activity through several mechanisms of action including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptotic cell death [9–11]. Here, CD38 is linked to plasma cell myeloma.